Keytruda (pembrolizumab) given accelerated approval for cervical cancer
Cervical cancer patients with disease progression on/after chemotherapy have a new treatment available in the form of Keytruda (pembrolizumab).
The FDA has given accelerated approval to Keytruda (pembrolizumab), following a new phase II KEYNOTE-158 trial.
According to oncological specialists, treatments have been lacking in the past for previously treated patients in this area. This approval, therefore, provides a much-needed option.
Read more about the accelerated approval in this OncLive article.